Br J Cancer:分次放疗联合血管靶向光动力疗法可增强对前列腺癌的抗肿瘤作用

2021-06-23 xiaozeng MedSci原创

分次放疗(FRT)联合雄激素剥夺疗法(ADT)是前列腺癌(PCa)的一种治疗选择,然而,三分之一的患者会出现复发,且患者后续的治疗选择有限。

分次放疗(FRT)联合雄激素剥夺疗法(ADT)是前列腺癌(PCa)的一种治疗选择,然而,三分之一的患者会出现复发,且患者后续的治疗选择有限。

此外,FRT和ADT具有显著的副作用。根治性手术(前列腺切除术)是PCa的另一种治疗选择,但也同样有显著的副作用。因此,急需制定改善PCa治疗结果和减少治疗副作用的治疗策略。

血管靶向光动力疗法(VTP)是一种新型的微创局部消融外科手术,其主要是通过自由基介导的快速破坏肿瘤血管系统来实现的。VTP可有效用于低风险小体积的PCa的局部消融,并已被作为放疗复发PCa的一种挽救疗法。


肿瘤血管系统的特征在于血管不成熟、渗透性增加、异常的分支以及低效的流动。FRT能够改变肿瘤微环境并促进短暂的“血管正常化”。在该研究中,研究人员假设,相比于FRT或VTP的单独治疗,二者联合的多模式治疗可以改善对PCa的控制。

VTP会导致移植瘤的生长延迟

研究人员在临床前PCa模型中研究了该假设,分析连续递送FRT和7天后的VTP治疗是否能够改善对TRAMP-C1 PCa侧翼移植瘤的控制。


结果显示,FRT能够诱导PCa侧翼移植瘤中的“血管正常化”变化,并改善相关血管功能,而相比于FRT或VTP的单独治疗,FRT后联合VTP治疗能够显著延迟移植瘤模型中的肿瘤生长,并提高总生存率。

新辅助FRT联合7天后VTP治疗可提高患者的疗效

总而言之,该研究结果揭示,FRT和VTP的联合治疗或可成为PCa治疗中的一种具有潜力的多模式治疗策略。这也为该多模式治疗策略提供了概念验证,为后续的早期临床试验提供一定的理论基础。


原始出处:

Sjoberg, H.T., Philippou, Y., Magnussen, A.L. et al. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. Br J Cancer (21 June 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1546334, encodeId=717f1546334a1, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Thu Jun 24 15:34:27 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976028, encodeId=604f9e60282c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Wed Jun 23 07:46:42 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976012, encodeId=91289e6012f5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jun 23 06:43:39 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041030, encodeId=b1561041030d0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 23 03:34:27 CST 2021, time=2021-06-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1546334, encodeId=717f1546334a1, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Thu Jun 24 15:34:27 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976028, encodeId=604f9e60282c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Wed Jun 23 07:46:42 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976012, encodeId=91289e6012f5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jun 23 06:43:39 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041030, encodeId=b1561041030d0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 23 03:34:27 CST 2021, time=2021-06-23, status=1, ipAttribution=)]
    2021-06-23 smart Ren

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1546334, encodeId=717f1546334a1, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Thu Jun 24 15:34:27 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976028, encodeId=604f9e60282c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Wed Jun 23 07:46:42 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976012, encodeId=91289e6012f5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jun 23 06:43:39 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041030, encodeId=b1561041030d0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 23 03:34:27 CST 2021, time=2021-06-23, status=1, ipAttribution=)]
    2021-06-23 yangchou

    好文章,谢谢分享。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1546334, encodeId=717f1546334a1, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Thu Jun 24 15:34:27 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976028, encodeId=604f9e60282c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Wed Jun 23 07:46:42 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976012, encodeId=91289e6012f5, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jun 23 06:43:39 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041030, encodeId=b1561041030d0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 23 03:34:27 CST 2021, time=2021-06-23, status=1, ipAttribution=)]
    2021-06-23 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:青少年动物产品摄入量与前列腺癌风险和死亡率之间的关系

该研究的结果证据表明,青少年期未加工牛肉摄入量,或可能为牛肉摄入量,与前列腺癌风险和死亡率降低相关。需要进一步研究早期暴露信息,以更好地了解这种关联。

BJU Int:前列腺切除术和盆腔淋巴结清扫术后淋巴囊肿明显减少

目前欧洲泌尿外科协会(EAU)的前列腺癌(PCa)指南建议,当估计的淋巴结阳性风险超过5%时,应对高风险和中风险患者进行扩展盆腔淋巴结清扫(ePLND)。事实上,尽管ePLND有着较高的并发症发生率,

JCO:高复发/死亡风险的前列腺癌患者根治性切除术后或可采用辅助放疗巩固

pN1期或pGleason评分8-10分和pT3/4期的前列腺癌患者,或可考虑采用辅助放射治疗,有望显著降低其全因死亡风险

Photoacoustics:通过光声光谱学和机器学习结合有益于诊断前列腺癌

最近,Photoacoustics杂志发文描述了机器学习方法的应用(包括无监督层次聚类和监督分类)诊断前列腺癌的光声频谱分析。

Radiology:多参数MRI在术前预测前列腺外侵犯中的应用

前列腺外侵犯(EPE)与男性前列腺癌根治性切除术后的手术切缘阳性、局部复发和生存率相关。由于EPE是否存在可影响手术时神经血管束的保留,因此EPE的术前预测意义重大。

BJU Int:PSMA PET和MRI预测中度和高度风险前列腺癌患者的早期结果

尽管大多数前列腺癌(PCa)患者在接受机器人辅助腹腔镜前列腺根治术(RARP)后将摆脱疾病的困扰,但相当比例的患者(20-40%)在首次检测不到前列腺特异性抗原(PSA)水平后会出现疾病的生化复发(B